Biogen Leans On Pipeline As Tecfidera, Spinraza See Q4 Sales Dip

Aducanumab Added To 2021 Guidance Amid Approval Optimism

The company sees aducanumab adding a modest boost to sales if approved, but there are another four Phase III programs with some major read-outs coming.

Biogen leans on aducanumab and other pipeline drugs as sales of Tecfidera and Spinraza slumped in Q4 and 2020. • Source: Shutterstock

Notwithstanding a three-month delay in a US Food and Drug Administration verdict, Biogen, Inc. is including the Alzheimer’s disease drug aducanumab in its 2021 guidance as dampened sales of its approved multiple sclerosis (MS) and spinal muscular atrophy (SMA) drugs have weighed on revenues. And if the amyloid-beta-targeting drug is not approved, the company maintains it still has a deep pipeline beyond aducanumab.

The Cambridge, Massachusetts-based company announced its fourth quarter and full year 2020 earnings on 3 February, announcing fourth quarter revenues of $2.85bn and full year revenues of $13

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

16 May 2025

• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

15 May 2025

• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

15 May 2025

• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.